Search research articles
Contact Us
Filters
Showing results (201-210 of 436) with videos related to
Page
of 44
Sort By:
Journal for Immunotherapy of Cancer
|
July 30, 2021
Overexpression of CD200 is a Stem Cell-Specific Mechanism of Immune Evasion in AML
Shelley Herbrich, Natalia Baran, Tianyu Cai, et al.
American Journal of Hematology
|
December 31, 2013
Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy
Elias Jabbour, Naval Daver, Richard Champlin, et al.
The Lancet. Haematology
|
December 22, 2015
Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study
Courtney D DiNardo, Naval Daver, Elias Jabbour, et al.
American Journal of Hematology
|
October 30, 2021
Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy
Koji Sasaki, Tapan Kadia, Kebede Begna, et al.
Biochimica Et Biophysica Acta. Molecular Cell Research
|
April 16, 2018
Role of MSC-derived galectin 3 in the AML microenvironment
Peter P Ruvolo, Vivian R Ruvolo, Jared K Burks, et al.
American Journal of Hematology
|
August 30, 2017
Clinical outcomes in adult patients with aplastic anemia: A single institution experience
Prajwal Boddu, Guillermo Garcia-Manero, Farhad Ravandi, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 18, 2021
Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome
Kiyomi Morita, Elias Jabbour, Farhad Ravandi, et al.
Oncotarget
|
November 2, 2017
Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy
Leonardo Mirandola, Elisa Pedretti, Jose A Figueroa, et al.
American Journal of Hematology
|
December 9, 2017
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
Courtney D DiNardo, Caitlin R Rausch, Christopher Benton, et al.
American Journal of Hematology
|
April 13, 2024
Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications
Tareq Abuasab, Gautam Borthakur, Rashmi Kanagal-Shamanna, et al.
Page
of 44
Search research articles
Search
Showing results (201-210 of 436) with videos related to
Sort By:
Page
of 44
Journal for Immunotherapy of Cancer
|
July 30, 2021
Overexpression of CD200 is a Stem Cell-Specific Mechanism of Immune Evasion in AML
Shelley Herbrich, Natalia Baran, Tianyu Cai, et al.
American Journal of Hematology
|
December 31, 2013
Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy
Elias Jabbour, Naval Daver, Richard Champlin, et al.
The Lancet. Haematology
|
December 22, 2015
Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study
Courtney D DiNardo, Naval Daver, Elias Jabbour, et al.
American Journal of Hematology
|
October 30, 2021
Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy
Koji Sasaki, Tapan Kadia, Kebede Begna, et al.
Biochimica Et Biophysica Acta. Molecular Cell Research
|
April 16, 2018
Role of MSC-derived galectin 3 in the AML microenvironment
Peter P Ruvolo, Vivian R Ruvolo, Jared K Burks, et al.
American Journal of Hematology
|
August 30, 2017
Clinical outcomes in adult patients with aplastic anemia: A single institution experience
Prajwal Boddu, Guillermo Garcia-Manero, Farhad Ravandi, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 18, 2021
Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome
Kiyomi Morita, Elias Jabbour, Farhad Ravandi, et al.
Oncotarget
|
November 2, 2017
Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy
Leonardo Mirandola, Elisa Pedretti, Jose A Figueroa, et al.
American Journal of Hematology
|
December 9, 2017
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
Courtney D DiNardo, Caitlin R Rausch, Christopher Benton, et al.
American Journal of Hematology
|
April 13, 2024
Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications
Tareq Abuasab, Gautam Borthakur, Rashmi Kanagal-Shamanna, et al.
Page
of 44